SPA
HAE icon

Sherbrooke Park Advisers’s Haemonetics HAE Stock Holding History

Sherbrooke Park Advisers’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,497
Closed -$222K – 623
2025
Q1 		$222K Buy
+3,497
New +$238K 0.1% 398
2024
Q1 		– Sell
-3,512
Closed -$300K – 903
2023
Q4 		$300K Buy
+3,512
New +$304K 0.14% 256

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sherbrooke Park Advisers's HAE Position: Q2 2025 in Review

Sherbrooke Park Advisers sold out of Haemonetics (HAE) in Q2 2025, closing a stake of 3,497 shares — an estimated $222K sold.

Sherbrooke Park Advisers first reported a position in HAE in Q4 2023 and held it in 2 quarters. The position peaked at $300K in Q4 2023. 298 funds tracked by Wall St. Rank hold HAE as of Q2 2025.

  • Sherbrooke Park Advisers reported no remaining Haemonetics position as of Q2 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 3,497 Haemonetics shares in Q2 2025, an estimated $222K.
  • Sherbrooke Park Advisers first reported a position in Haemonetics in Q4 2023 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Haemonetics position peaked at $300K in Q4 2023.
  • 298 funds tracked by Wall St. Rank held Haemonetics as of Q2 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.